000130133 001__ 130133 000130133 005__ 20240122171020.0 000130133 0247_ $$2doi$$a10.1016/j.ijcard.2014.07.098 000130133 0248_ $$2sideral$$a136389 000130133 037__ $$aART-2014-136389 000130133 041__ $$aeng 000130133 100__ $$0(orcid)0000-0002-3132-2171$$aDiez-Manglano J$$uUniversidad de Zaragoza 000130133 245__ $$aAdherence to guidelines and mortality in atrial fibrillation 000130133 260__ $$c2014 000130133 5060_ $$aAccess copy available to the general public$$fUnrestricted 000130133 5203_ $$aObjective Determining the adherence to ACC/AHA/ESC 2006 guidelines and its influence on the survival of patients with atrial fibrillation. Methods Prospective observational study of patients discharged during 2007 from an Internal Medicine department with a main or secondary diagnose of atrial fibrillation. The stroke risk was estimated with the CHADS2 score. The follow-up was carried out in outpatient medical office or via telephone. Results We included 259 patients (mean age 80.9 years); 73% of them had a high risk of stroke. Oral anticoagulants were administered to 134 (51.7%), and antiplatelet drugs to 71 (27%) patients. A rate control strategy was chosen for 155 (59.8%) patients and a rhythm control one for 28 (10.8%). In 100 (38.6%) patients, treatment was adherent to the guidelines. Adherence to the guidelines was associated with age (0.95 95%CI 0.92–0.99; p = 0.03), contraindication to the use of oral anticoagulants (0.38 95%CI 0.18–0.81; p = 0.01) and mitral valve heart disease/valvular prosthesis (2.10 95%CI 1.04–4.25; p = 0.04). The median follow-up was 727 days, and 191 patients died. Patients treated according to the guidelines had a higher rate of survival during the first three years (0.47 vs. 0.36; p = 0.049). The use of oral anticoagulants was associated with a higher probability of survival over a 5 year period (0.34 vs 0.21; p = 0.001) and the rate control strategy during the first year (0.69 vs 0.57; p = 0.04). Conclusions In the real world, the treatment of atrial fibrillation according to the guidelines is associated with improved survival for up to three years during follow-up. 000130133 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000130133 590__ $$a4.036$$b2014 000130133 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b29 / 123 = 0.236$$c2014$$dQ1$$eT1 000130133 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000130133 700__ $$aGomes-Martín J 000130133 700__ $$aAl-Cheikh-Felices P 000130133 700__ $$aIsasi de Isasmendi Pérez S 000130133 700__ $$aDíez-Angulo R 000130133 700__ $$aClemente-Sarasa C 000130133 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000130133 773__ $$g176, 2 (2014), 430-436$$pInt. j. cardiol.$$tINTERNATIONAL JOURNAL OF CARDIOLOGY$$x0167-5273 000130133 8564_ $$s244397$$uhttps://zaguan.unizar.es/record/130133/files/texto_completo.pdf$$yPostprint 000130133 8564_ $$s961562$$uhttps://zaguan.unizar.es/record/130133/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000130133 909CO $$ooai:zaguan.unizar.es:130133$$particulos$$pdriver 000130133 951__ $$a2024-01-22-15:28:37 000130133 980__ $$aARTICLE